Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

175.41USD
8 Dec 2017
Change (% chg)

$1.45 (+0.83%)
Prev Close
$173.96
Open
$174.43
Day's High
$175.97
Day's Low
$173.43
Volume
3,336,250
Avg. Vol
2,588,102
52-wk High
$191.10
52-wk Low
$138.83

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $127,332.00
Shares Outstanding(Mil.): 725.91
Dividend: 1.15
Yield (%): 2.62

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Carmot Enters A Multi-Year Drug Discovery Collaboration With Amgen

* CARMOT ENTERS A MULTI-YEAR DRUG DISCOVERY COLLABORATION WITH AMGEN

Dec 06 2017

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

Dec 05 2017

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS

Dec 04 2017

FDA approves heart protection claims for Amgen cholesterol drug

Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday.

Dec 01 2017

FDA approves heart protection claims for Amgen cholesterol drug

Dec 1 Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday.

Dec 01 2017

BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

* AIMOVIG™ (ERENUMAB) PHASE 3 STRIVE DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE DEMONSTRATE SIGNIFICANT, SUSTAINED EFFICACY IN MIGRAINE PREVENTION Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Amgen launches Enbrel Mini with Autotouch in U.S.

* Amgen launches the Enbrel Mini single-dose prefilled cartridge with autotouch reusable autoinjector that is ergonomically designed for patients

Nov 17 2017

BRIEF-Temasek Holdings takes share stake in Vantiv Inc, raises share stake in Amgen

* Temasek Holdings (Private) Ltd takes share stake of 982,057 Class A shares in Vantiv Inc - SEC filing

Nov 14 2017

BRIEF-Amgen receives positive CHMP opinion to expand use of Nplate in pediatric patients with chronic immune thrombocytopenic purpura

* Amgen receives positive CHMP opinion to expand use of Nplate® (romiplostim) in pediatric patients with chronic immune thrombocytopenic purpura

Nov 10 2017

BRIEF-Amgen and Allergan receive positive chmp opinion for ABP 215

* Amgen and Allergan receive positive CHMP opinion for ABP 215 (biosimilar bevacizumab) for the treatment of certain types of cancer

Nov 10 2017

Earnings vs. Estimates